Please assess the completion status of the following clinical trial:

Trial Title: Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria for probable Alzheimer's Disease~* Has completed participation in solanezumab Study LZAM or Study LZAN through 80 weeks~* Must continue to have a reliable caregiver who is in frequent contact with the patient for the entire study~* Must have good vein access to administer infusions~* Agrees not to participate in studies of any other investigational compounds for the duration of their participation in Study LZAO~Exclusion Criteria:~* Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational drug or device or off-label use of a drug or device (other than the study drug/device used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study~* Meets LZAM or LZAN discontinuation criteria at the end of treatment in LZAM or LZAN study

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Solanezumab (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).